Delcath Systems, Inc.

Healthcare · Medical Devices · United States

Last price 14.64 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 507.99M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in...